InvestSMART

Australian Clinical Labs Limited (ASX: ACL) - Announcements

Current share price for ACL : $2.920 0.04 (1.39%)+

ASX company news and announcements for Australian Clinical Labs Limited (ACL) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Australian Clinical Labs Limited (ACL) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Australian Clinical Labs Limited (ACL), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Australian Clinical Labs Limited (ACL)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$545 Trading Halt 24 Aug 2006 9:28AM n/a $2.920 n/a
$545 Commitments Test Entity - Fourth Quarter Report 1 Aug 2006 8:52AM $0.960 $2.920 risen by 204.17%
$545 Extension of Takeover Bid 31 Jul 2006 3:32PM $0.980 $2.920 risen by 197.96%
$545 Alchemia gains more than 90% of Meditech 25 Jul 2006 9:08AM $1.070 $2.920 risen by 172.90%
$545 Alchemia Offer Period Extension 23 Jun 2006 4:20PM $1.150 $2.920 risen by 153.91%
$545 Section 630(3) Notice 31 May 2006 9:14AM $1.240 $2.920 risen by 135.48%
$545 Extension of Takeover Bid 2 May 2006 1:52PM $1.320 $2.920 risen by 121.21%
$545 Commitments Test Entity - Third Quarter Report 19 Apr 2006 5:32PM $1.240 $2.920 risen by 135.48%
$545 Awarded Queensland Government SSIF grant 10 Apr 2006 9:03AM $1.320 $2.920 risen by 121.21%
$545 Alchemia generic drug set to benefit from Arixtra success 17 Mar 2006 2:17PM $1.395 $2.920 risen by 109.32%
$545 Alchemia and Meditech to merge 9 Mar 2006 9:42AM $1.230 $2.920 risen by 137.40%
$545 Half Yearly Report & Half Year Accounts to 31 Dec 2005 24 Feb 2006 11:27AM $1.230 $2.920 risen by 137.40%
$545 Positive Outlook for Alchemia drug 16 Feb 2006 12:42PM $1.115 $2.920 risen by 161.88%
$545 Synthetic Heparin Update 8 Feb 2006 1:34PM $1.120 $2.920 risen by 160.71%
$545 Commitments Test Entity - Second Quarter Report 31 Jan 2006 10:19AM $1.140 $2.920 risen by 156.14%
$545 Alchemia and TetraQ collaborate on new pain treatments 2 Dec 2005 10:04AM $1.325 $2.920 risen by 120.38%
$545 Alchemia offered $2.9m Commercial Ready grant 7 Nov 2005 9:00AM $1.385 $2.920 risen by 110.83%
$545 Granted US Patent 3 Nov 2005 3:59PM $1.385 $2.920 risen by 110.83%
$545 Capital Raising to Progress Promising New Drug Candidates 3 Nov 2005 9:48AM $1.385 $2.920 risen by 110.83%
$545 Trading Halt 1 Nov 2005 3:02PM $1.400 $2.920 risen by 108.57%
$545 Commitments Test Entity - First Quarter Report 25 Oct 2005 10:59AM $1.185 $2.920 risen by 146.41%
$545 Update on progress of Synthetic Heparin 30 Sep 2005 12:55PM $1.090 $2.920 risen by 167.89%
$545 Alchemia achieves positive results 22 Sep 2005 4:13PM $1.035 $2.920 risen by 182.13%
$545 Positive safety results from Arixtra trial 6 Sep 2005 3:02PM $0.790 $2.920 risen by 269.62%
$545 Preliminary Final Report/Full Year Accounts 19 Aug 2005 9:28AM $0.790 $2.920 risen by 269.62%

976 - 1000 of 1019 results

Page 40 of 41

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.